<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567616</url>
  </required_header>
  <id_info>
    <org_study_id>M16-085</org_study_id>
    <secondary_id>2017-004232-11</secondary_id>
    <nct_id>NCT03567616</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and preliminary efficacy of venetoclax combined
      with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R)
      multiple myeloma (MM) who have received at least 1 prior line of therapy. The study will
      consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the
      participants will be divided into 2 cohorts, participants positive for t(11;14) translocation
      and participants negative for t(11;14) translocation.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Safety
  </why_stopped>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">January 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From first dose of study drug until 30 days following last dose of study drug</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>ORR is defined as the percentage of participants experiencing a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <description>PFS is defined as the number of days from the date of first dose of any study drug to the date of disease progression or death, whichever occurs first. All disease progression will be included regardless whether the event occurred during or after the participant was taking any study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>DOR defined as the number of days from the date of that participant's first documented response (PR or better) to the date of first documented disease progression (PD) or death due to multiple myeloma, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression (TTP)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>TPP is defined as the number of days from the date of first dose to the date of first documented PD or death due to MM, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose-Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-Escalation Phase participants will administer venetoclax (various doses) + pomalidomide + dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase: Arm A t(11;14) Positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion Phase Arm A in participants positive for t(11;14) translocation will administer venetoclax + pomalidomide + dexamethasone .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase: Arm B t(11;14) Negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion Phase Arm B in participants negative for t(11;14) translocation will administer venetoclax + pomalidomide + dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet; oral</description>
    <arm_group_label>Dose-Escalation Phase</arm_group_label>
    <arm_group_label>Expansion Phase: Arm A t(11;14) Positive</arm_group_label>
    <arm_group_label>Expansion Phase: Arm B t(11;14) Negative</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>capsule; oral</description>
    <arm_group_label>Dose-Escalation Phase</arm_group_label>
    <arm_group_label>Expansion Phase: Arm A t(11;14) Positive</arm_group_label>
    <arm_group_label>Expansion Phase: Arm B t(11;14) Negative</arm_group_label>
    <other_name>Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>administered orally</description>
    <arm_group_label>Dose-Escalation Phase</arm_group_label>
    <arm_group_label>Expansion Phase: Arm A t(11;14) Positive</arm_group_label>
    <arm_group_label>Expansion Phase: Arm B t(11;14) Negative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory (R/R) multiple myeloma (MM) with documented evidence of
             progression during or after the participant's last treatment regimen.

          -  Measurable disease as described in the protocol.

          -  Received at least 1 prior line of therapy, as described in the protocol.

          -  Must meet prior antimyeloma treatment parameters, as described in the protocol, and
             includes:

          -  Received at least 2 consecutive cycles of lenalidomide or a lenalidomide containing
             regimen

          -  Refractory to lenalidomide

          -  Exposed to a proteasome inhibitor (PI) alone or in combination with another agent.

          -  Had a response of partial response (PR) or better to prior therapy based on the
             investigator's determination of response as defined by International Myeloma Working
             Group (IMWG) criteria.

          -  Has t(11;14) status as described in the protocol and meets the following criteria:

          -  For Part 1: MM participants independent of cytogenetic profile.

          -  For Part 2, Arm A: participant must be t(11;14) positive.

          -  For Part 2, Arm B: participant must be t(11;14) negative.

          -  An Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2.

          -  Adequate kidney, liver and hematologic laboratory values.

        Exclusion Criteria:

          -  Previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment
             with pomalidomide

          -  Known sensitivity to any IMiDs

          -  Allogenic or syngeneic stem cell transplant within 6 months before the first dose of
             study drug or active ongoing graft versus host disease

          -  Autologous stem cell transplant within 12 weeks before the first dose of study drug

          -  Known meningeal involvement of MM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John B. Amos Cancer Center - C /ID# 202055</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center /ID# 201292</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205-2528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute /ID# 201297</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 201287</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital /ID# 200805</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Cancer Center /ID# 202443</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University /ID# 205582</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care, Aurora Cancer Center /ID# 201153</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226-3436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 200957</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron /ID# 200967</name>
      <address>
        <city>Barcelona</city>
        <zip>08035-999999</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Germans Trias I /ID# 200959</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 200969</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Univ de Salamanca /ID# 200958</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary /ID# 202238</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hospitals Birmingham NHS Foundation trust /ID# 203188</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James University Hospital /ID# 202243</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Univ Hosp /ID# 202240</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital, The Ro /ID# 202242</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Multiple Myeloma (MM)</keyword>
  <keyword>Relapsed or Refractory (R/R)</keyword>
  <keyword>venetoclax</keyword>
  <keyword>pomalidomide</keyword>
  <keyword>dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

